Anti-TRPV5 Antibody,Alomone Labs,ACC-035
Alomone Labs is pleased to offer a highly specific antibody directed against an epitope of human TRPV5.Anti-TRPV5 Antibody(#ACC-035) can be used in western blot, immunocytochemistry and immunohistochemistry applications. It has been designed to recognize TRPV5 from human, mouse and rat samples. Anti-TRPV5 Antibody –(Carrier Free) (#ACC-035-CF). This ready-to-use, carrier-free formulation is free of BSA and sodium azide, making it ideal for conjugation, sensitive downstream applications and specialized assay development. The size of this version is0.2 mlat a concentration of1 mg/ml, and It has been designed to recognize TRPV5 from human, mouse and rat samples. Carrier Free: Anti-TRPV5 Antibody –(Carrier Free) (#ACC-035-CF). This ready-to-use, carrier-free formulation is free of BSA and sodium azide, making it ideal for conjugation, sensitive downstream applications and specialized assay development. The size of this version is0.2 mlat a concentration of1 mg/ml, and It has been designed to recognize TRPV5 from human, mouse and rat samples.
Host
Rabbit
Reactivity
Human,Mouse,Rat
Application
ICC, IF, IHC, WB
Platform ID
BAB340838372

Alomone Labs
Contact
Tel: +972-2-587-2202
Fax: +972-2-587-1101
Email:
Product Specifications
Specifications
NameAnti-TRPV5 Antibody
Cat. No.ACC-035
Accession NumberQ8NDW5
Gene ID (Entrez)56302
HostRabbit
RRIDAB_2039793
IsotypeRabbit IgG.
ReactivityHuman,Mouse,Rat
ApplicationICC, IF, IHC, WB
ClonalityPolyclonal
ImmunogenPeptide (C)GLNLSEGDGEEVYHF, corresponding to amino acid residues 715-729 of human TRPV5 (Accession Q9NQA5 ). Intracellular, C-terminus.
Appearance/FormLyophilized_Powder
Reconstitution0.2 ml double distilled water (DDW).
StorageThe antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>IHC Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.
